-
Publication Venue For
-
Atrial fibrillation ablation in practice: assessing CABANA generalizability..
40:1257-1264.
2019
-
Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial..
40:743-751.
2019
-
Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies..
40:621-631.
2019
-
Fourth universal definition of myocardial infarction (2018)..
40:237-269.
2019
-
Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF..
39:4255-4256.
2018
-
Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials..
39:3810-3820.
2018
-
Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry..
39:3701-3711.
2018
-
The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial..
39:3464-3471.
2018
-
Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation..
39:2942-2955.
2018
-
Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe..
39:2932-2941.
2018
-
Transitioning fromusual care to biomarkerbased personalized and precisionmedicine in heart failure: Call for action.
39:2793-2798.
2018
-
Uninterrupted apixaban for atrial fibrillation ablation is a reasonable alternative, but what is the significance of silent cerebral infarctions?.
39:2956-2958.
2018
-
Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke..
39:2376-2386.
2018
-
Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome..
39:2460-2468.
2018
-
The incidence and prognostic implications of worsening right ventricular function after surgical or transcatheter aortic valve replacement: insights from PARTNER IIA..
39:2659-2667.
2018
-
Application of net reclassification index to non-nested and point-based risk prediction models: a review.
2018
-
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials..
39:2208-2216.
2018
-
Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative..
39:1687-1697.
2018
-
Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation..
39:1706-1708.
2018
-
Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug?.
39:1438-1441.
2018
-
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score..
39:477-485.
2018
-
Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?.
39:450-452.
2018
-
Oral anticoagulation: a step toward solving the puzzle of dementia related to atrial fibrillation?.
39:461-463.
2018
-
Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy..
39:193-200.
2018
-
Staging classification of aortic stenosis based on the extent of cardiac damage..
38:3351-3358.
2017
-
Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke..
38:2827-2835.
2017
-
Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial..
38:2813-2822.
2017
-
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary..
38:2137-2149.
2017
-
HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm..
38:1687-1689.
2017
-
Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges..
38:1805-1814.
2017
-
Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial..
38:648-660.
2017
-
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1..
38:852-859.
2017
-
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2..
38:860-868.
2017
-
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial..
38:804-810.
2017
-
A review of sex-specific benefits and risks of antithrombotic therapy in acute coronary syndrome..
38:165-171.
2017
-
A view from the side-line..
37:3488-3489.
2016
-
Anticoagulation in coronary intervention..
37:3376-3385.
2016
-
Genetic cardiovascular risk prediction: are we already there?.
37:3279-3281.
2016
-
Troponins in equipoise..
37:3333-3334.
2016
-
Risk stratification in non-ST elevation acute coronary syndromes: searching for the right formula..
37:3111-3113.
2016
-
The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial..
37:2869-2878.
2016
-
Highly sensitive troponin and coronary computed tomography angiography in the evaluation of suspected acute coronary syndrome in the emergency department..
37:2397-2405.
2016
-
Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction..
37:2276-2286.
2016
-
Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease..
37:1993-2001.
2016
-
Genetic variants and disease: correlate or cause?.
37:1476-1478.
2016
-
Left atrial appendage to great cardiac vein fistula complicating watchman left atrial appendage closure..
37:1602.
2016
-
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation..
37:1582-1590.
2016
-
Assessing generalizability of trial results in general practice..
37:1154-1157.
2016
-
Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma..
37:1143-1144.
2016
-
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
2016
-
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
2016
-
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome..
37:412-422.
2016
-
CardioPulse: Platelet inhibitors and their differences..
37:323-326.
2016
-
Lessons learned and a look to the future: The chronic ischemic heart disease (CICD) pilot registry.
37:161-163.
2016
-
The ORBIT bleeding score: A simple bedside score to assess bleeding risk in atrial fibrillation.
36:3258-3264.
2015
-
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial..
36:3268-3275.
2015
-
Nox4 NADPH oxidase: emerging from the veil of darkness..
36:3457-3459.
2015
-
Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction..
36:2733-2741.
2015
-
Augmenting outcomes in patients with advanced heart failure..
36:2276-2278.
2015
-
Cardiovascular precision medicine: hope or hype?.
36:1842-1843.
2015
-
Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium..
36:1851-1877.
2015
-
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes..
36:1901-1912.
2015
-
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention..
36:1762-1771.
2015
-
Current worldwide nuclear cardiology practices and radiation exposure: results from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS)..
36:1689-1696.
2015
-
Should patients on vitamin K antagonists be treated differently?.
36:1431-1433.
2015
-
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial..
36:1264-1272.
2015
-
Management of cardiogenic shock..
36:1223-1230.
2015
-
The end of an electrocardiographic dogma: a prominent R wave in V1 is caused by a lateral not posterior myocardial infarction-new evidence based on contrast-enhanced cardiac magnetic resonance-electrocardiogram correlations..
36:959-964.
2015
-
Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program..
36:669-675.
2015
-
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial..
36:385-92a.
2015
-
Can copeptin emerge from the growing shadow of the troponins?.
36:333-336.
2015
-
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
36:288-296.
2015
-
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial..
36:288-296.
2015
-
LCZ696: too good to be true?.
36:410-412.
2015
-
Current worldwide nuclear cardiology practices andradiationexposure: Results from the 65country IAEA nuclear cardiology protocols cross-sectional study (INCAPS).
36:1689-1696.
2015
-
Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention..
35:3323-3325.
2014
-
Chest pain in patients with heart failure: why history may matter..
35:3408-3409.
2014
-
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial..
35:3377-3385.
2014
-
Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure..
35:3434-3441.
2014
-
Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry..
35:2864-2872.
2014
-
Ameliorating reperfusion injury in STEMI: dead or alive?.
35:2504-2506.
2014
-
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial..
35:2516-2523.
2014
-
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial..
35:2524-2529.
2014
-
Prognostic implication of the new peri-PCI (type 4a) myocardial infarction definition according to the third universal definition of myocardial infarction in patients with NSTE ACS.
35:138-138.
2014
-
Diagnosis of pheochromocytoma on physical examination..
35:1705.
2014
-
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial..
35:1864-1872.
2014
-
Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?.
35:1834-1835.
2014
-
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
35:1873-1880.
2014
-
Statistical considerations in economic evaluations: a guide for cardiologists..
35:1652-1656.
2014
-
Early management of atrial fibrillation to prevent cardiovascular complications..
35:1448-1456.
2014
-
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial..
35:1541-1550.
2014
-
The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions..
35:1526-1532.
2014
-
The enigmatic search for optimal DAPT duration..
35:951-954.
2014
-
Large simple trials: really, it can't be that simple!.
35:549-551.
2014
-
Large streamlined trials in cardiovascular disease..
35:544-548.
2014
-
The appropriate and justified use of medical radiation in cardiovascular imaging: a position document of the ESC Associations of Cardiovascular Imaging, Percutaneous Cardiovascular Interventions and Electrophysiology..
35:665-672.
2014
-
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial..
35:224-232.
2014
-
Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT..
35:106-115.
2014
-
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
35:242-249.
2014
-
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
35:233-241.
2014
-
Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
34:3342-3352.
2013
-
Learning from regional heterogeneity in outcomes of patients with acute myocardial infarction..
34:3171-3172.
2013
-
Physical activity in patients with stable coronary heart disease: an international perspective..
34:3286-3293.
2013
-
Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial..
34:3117-3127.
2013
-
Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF..
34:3128-3136.
2013
-
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial..
34:2481-2489.
2013
-
Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial..
34:2271-2280.
2013
-
Atrial fibrillation: a spectrum of risk with a uniform treatment effect of novel anticoagulants?.
34:2429-2431.
2013
-
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial..
34:2464-2471.
2013
-
Relationship between diabetes, race, obesity and outcomes in patients with acute coronary syndrome: a pool analysis from randomized trials.
34:787-787.
2013
-
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial..
34:1723-1731.
2013
-
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis..
34:1670-1680.
2013
-
Biomarkers in atrial fibrillation: a clinical review..
34:1475-1480.
2013
-
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis..
34:1204-1214.
2013
-
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial..
34:835-843.
2013
-
Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint..
34:903-908.
2013
-
Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review..
34:894-902d.
2013
-
Spousal depression, anxiety, and suicide after myocardial infarction..
34:649-656.
2013
-
How country-specific should a country-specific cost-effectiveness analysis be?.
34:166-167.
2013
-
Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy..
34:39-47.
2013
-
Mechanical dyssynchrony evaluated by tissue Doppler cross-correlation analysis is associated with long-term survival in patients after cardiac resynchronization therapy..
34:48-56.
2013
-
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial..
33:2821-2830.
2012
-
Clinical update: Remaining challenges and opportunities for improvement in percutaneous transradial coronary procedures..
33:2521-2526.
2012
-
Road mapping ATLAS ACS 2: are we there yet?.
33:2510-2512.
2012
-
Third universal definition of myocardial infarction..
33:2551-2567.
2012
-
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study..
33:2151-2162.
2012
-
Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea..
33:2197-2205.
2012
-
Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section..
33:2265-2271.
2012
-
Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure..
33:2317-2324.
2012
-
The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction..
33:2044-2053.
2012
-
Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community..
33:1734-1741.
2012
-
Putting risk prediction in atrial fibrillation into perspective..
33:1431-1433.
2012
-
Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome..
33:1095-1104.
2012
-
Toward a therapeutic window for antiplatelet therapy in the elderly..
33:1187-1189.
2012
-
Long-term prognosis associated with J-point elevation in a large middle-aged biracial cohort: the ARIC study..
32:3098-3106.
2011
-
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial..
32:2781-2789.
2011
-
Contributions of peak expiratory flow to assessment of acute decompensated heart failure: insights from ASCEND-HF.
32:964-964.
2011
-
Gender paradox: higher incidence but lower one-year mortality with bleeding among women compared with men following fibrinolysis for acute ST-elevation myocardial infarction.
32:166-166.
2011
-
The independent prognostic value of hyponatremia in a cohort of heart failure patients: analysis from the Duke databank for cardiovascular disease.
32:134-134.
2011
-
Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the APEX-AMI trial.
32:872-872.
2011
-
Who should have a routine early invasive approach after fibrinolytic therapy?.
32:1961-1963.
2011
-
Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology..
32:1673-1686.
2011
-
Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT..
32:1622-1630.
2011
-
The future of clinical trials in secondary prevention after acute coronary syndromes..
32:1583-1589.
2011
-
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study..
32:1519-1534.
2011
-
Additional impact of morning haemostatic risk factors and morning blood pressure surge on stroke risk in older Japanese hypertensive patients..
32:574-580.
2011
-
Fractal analysis of retinal microvasculature and coronary heart disease mortality..
32:422-429.
2011
-
Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis..
31:2156-2169.
2010
-
Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care..
31:1881-1889.
2010
-
Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial..
31:1701-1707.
2010
-
Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial..
31:1708-1716.
2010
-
Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective..
31:1328-1336.
2010
-
Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events..
31:1449-1456.
2010
-
Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention..
31:1181-1187.
2010
-
Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis..
31:1257-1265.
2010
-
The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences..
31:1188-1196.
2010
-
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria..
31:806-814.
2010
-
Towards a new order in cardiovascular medicine: re-engineering through global collaboration..
31:911-917.
2010
-
Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative..
31:703-711.
2010
-
Clinical trials and registries in cardiovascular disease: competitive or complementary?.
31:520-521.
2010
-
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events..
31:667-675.
2010
-
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction..
31:573-581.
2010
-
The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative..
31:552-560.
2010
-
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications..
31:227-235.
2010
-
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial..
31:211-221.
2010
-
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes..
31:50-58.
2010
-
Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention..
30:2575-2583.
2009
-
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry..
30:2318-2326.
2009
-
Early in-ospital worsening heart failure predicts adverse outcome in patients.
30:719-719.
2009
-
Echocardiographic predictors of long-term survival in adults with pulmonary hypertension.
30:115-115.
2009
-
Effects of the new vasodilator relaxin for the treatment of patients with acute heart failure and normal to elevated blood pressure: results of a phase 2b study (Pre-RELAX-AHF).
30:424-425.
2009
-
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial..
30:2226-2232.
2009
-
Impact of anemia in patients with pulmonary hypertension.
30:260-260.
2009
-
Impact of incidentally discovered patent foramen ovale and its operative repair on long-term survival.
30:6-6.
2009
-
Improved pulmonary insufficiency with inhaled vasodilator assessed by cardiac magnetic resonance imaging.
30:811-811.
2009
-
Increased symptom-improvement with the novel vasodilator, relaxin, in Acute Heart Failure (AHF) patients with elevated blood pressure. Results from the Pre-RELAX-AHF study.
30:164-164.
2009
-
Novel intravascular defibrillator (InnerPulse PICD): defibrillation thresholds of PICD compared to Medtronic ICD in a canine model.
30:276-276.
2009
-
Patient-reported dyspnea in acute heart failure trials. Use of the Likert and the visual analog scales in the pre-RELAX AHF study.
30:445-446.
2009
-
Prevalence & prognostic importance of micro-& macro-albuminuria in heart failure- an analysis from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme.
30:876-876.
2009
-
Pulmonary vasodilator challenge predicts survival in patients with various etiologies of pulmonary hypertension.
30:899-900.
2009
-
Racial disparities in survival in patients with pulmonary hypertension.
30:513-513.
2009
-
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis..
30:2213-2219.
2009
-
Time to treatment and vasodilator efficacy in acute heart failure: Results from the Pre-RELAX-AHF study.
30:424-424.
2009
-
Worsening renal function in acute heart failure: change in BP and effects of relaxin.
30:1020-1021.
2009
-
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial..
30:2019-2028.
2009
-
Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial..
30:1457-1466.
2009
-
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)..
30:1450-1456.
2009
-
Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials..
30:1245-1253.
2009
-
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes..
30:1195-1202.
2009
-
Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery..
30:995-1004.
2009
-
Reperfusion ventricular arrhythmia 'bursts' predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction..
30:757-764.
2009
-
Whose heart will get broken? Troponin testing and future heart failure..
30:755-756.
2009
-
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes..
30:655-661.
2009
-
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure..
30:338-345.
2009
-
ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007..
30:152-161.
2009
-
Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study..
30:56-65.
2009
-
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme..
29:3022-3028.
2008
-
Is thrombogenesis related to residual platelet function in ischaemic heart disease?: Reply.
29:3065-3066.
2008
-
Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry..
29:3052-3060.
2008
-
Erythropoietin, haemoglobin, heart failure, and mortality: Reply.
29:2695-2696.
2008
-
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme..
29:2641-2650.
2008
-
Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes..
29:2480-2488.
2008
-
Acute severe hypertension has high morbidity, mortality, and readmission rates: results from the STAT registry.
29:513-513.
2008
-
An RNA aptamer inhibiting factor IXa and its complementary oligonucleotide antidote.
29:328-328.
2008
-
Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients..
29:2212-2217.
2008
-
Cognitive function and anticoagulation control in patients with atrial fibrillation.
29:258-258.
2008
-
Endoscopic vein harvesting is a strong independent predictor of vein graft failure in patients undergoing coronary artery bypass graft surgery.
29:284-285.
2008
-
Has the frequency of bleeding improved over time for patients presenting with an acute coronary syndrome? The GRACE Registry.
29:326-326.
2008
-
Impact of incidentally discovered patent foramen ovale and its repair on perioperative outcomes in 13,260 cardiothoracic surgery patients.
29:124-124.
2008
-
Late recanalization of infarct related artery has no impact on clinical outcomes regardless of ejection fraction: Results from the Occluded Artery Trial (OAT).
29:679-679.
2008
-
Mechanical complications are uncommon in STEMI treated with primary-PCI: insights from APEX-AMI.
29:137-138.
2008
-
Mortality after cardiogenic shock remains high in ST-elevation myocardial infarction treated with primary PCI: insights from APEX AMI.
29:447-447.
2008
-
Prevalence and predictors of dyssynchrony as determined by gated SPECT perfusion imaging in patients with left ventricular dysfunction.
29:5-5.
2008
-
Surgical treatment of anomalous coronary arteries passing between the great vessels in older adults may not improve survival.
29:7-7.
2008
-
Triple combination Ezetimibe/Simvastatin plus extended release Niacin therapy improves ratios of ApoB/ApoA-I containing lipoproteins in hyperlipidemia patients.
29:345-346.
2008
-
A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF..
29:1983-1991.
2008
-
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial..
29:1827-1833.
2008
-
Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad..
29:1729-1738.
2008
-
Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients..
29:1510-1515.
2008
-
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..
29:1377-1385.
2008
-
Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative..
29:1103-1109.
2008
-
Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study..
29:1127-1135.
2008
-
Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy..
29:871-879.
2008
-
Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients..
29:1011-1018.
2008
-
Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb..
29:880-887.
2008
-
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study..
29:748-756.
2008
-
Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go..
29:609-617.
2008
-
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment..
29:315-323.
2008
-
Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI..
28:2850-2857.
2007
-
When renal and cardiac insufficiencies intersect: is there a role for natriuretic peptide testing in the 'cardio-renal syndrome'?.
28:2960-2961.
2007
-
Cardiovascular disease on a global scale: defining the path forward for research and practice..
28:2678-2684.
2007
-
A new model for predicting mortality in acute ST elevation myocardial infarction treated with primary PCI: results from the APEX AMI trial.
28:59-59.
2007
-
Adverse outcomes in fibrinolytic-based facilitated PCI: insights from the ASSENT-4 PCI electrocardiographic substudy.
28:59-59.
2007
-
Atrial fibrillation is associated with worse outcomes in ST elevation and non ST elevation acute coronary syndromes.
28:259-260.
2007
-
Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial.
28:516-516.
2007
-
Can we predict non-fatal cardiovascular events in acute coronary syndrome? The Global Registry of Acute Coronary Events.
28:689-689.
2007
-
Comparison of outcomes between patients undergoing percutaneous coronary stent implantation with eptifibatide and abciximab: an analysis using propensity score methods.
28:184-184.
2007
-
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis..
28:2077-2086.
2007
-
Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women..
28:2064-2069.
2007
-
Outcomes for stenting in single and multivessel coronary artery disease using established and novel paclitaxel eluting stent platforms: COSTAR II.
28:577-577.
2007
-
Predictors of angiographic success and relationship to clinical outcomes during primary PCI for ST elevation acute myocardial infarction: insights from APEX-AMI.
28:660-660.
2007
-
Short-term outcomes are at least as good with drug eluting vs. bare metal stents: insights from APEX AMI.
28:9-9.
2007
-
Similar association between age and outcomes in high-risk ACS patients treated with enoxaparin or unfractionated heparin.
28:218-218.
2007
-
The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial.
28:187-187.
2007
-
Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab.
28:384-385.
2007
-
Retinal vessel diameter and cardiovascular mortality: pooled data analysis from two older populations..
28:1984-1992.
2007
-
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes..
28:1598-1660.
2007
-
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction..
28:1709-1716.
2007
-
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes..
28:1193-1204.
2007
-
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study..
28:1109-1116.
2007
-
Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial..
28:1079-1084.
2007
-
Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry..
28:980-988.
2007
-
Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial..
28:685-691.
2007
-
Ruminating on OAT: is the case closed?.
28:531-532.
2007
-
The cost of implantable defibrillators: how the perception of reality depends on perspective.
28:386-387.
2007
-
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials..
28:425-432.
2007
-
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function..
28:326-333.
2007
-
The high cost of implantable defibrillators..
28:388-391.
2007
-
The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction..
28:415-424.
2007
-
Diabetes mellitus and insulin therapy in infective endocarditis..
28:3-4.
2007
-
Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial..
27:3027-3032.
2006
-
Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire?.
27:2737-2739.
2006
-
Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes..
27:2956-2961.
2006
-
Is acute heart failure a highly prevalent orphan disease?.
27:2619-2620.
2006
-
Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study..
27:2516-2523.
2006
-
Glucose, insulin, and acute myocardial infarction: Reply [4].
27:2142-2143.
2006
-
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation)..
27:1979-2030.
2006
-
A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study..
27:1530-1538.
2006
-
International variation in invasive care of the elderly with acute coronary syndromes..
27:1558-1564.
2006
-
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study..
27:1289-1297.
2006
-
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..
27:1447-1458.
2006
-
Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial..
27:1198-1206.
2006
-
Persistent and reversible cardiac dysfunction among amateur marathon runners..
27:1079-1084.
2006
-
Aborted myocardial infarction: a new target for reperfusion therapy..
27:901-904.
2006
-
NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy..
27:839-845.
2006
-
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes..
27:527-533.
2006
-
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction..
27:419-426.
2006
-
How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts..
27:323-329.
2006
-
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study..
27:330-337.
2006
-
Predictors of mortality and morbidity in patients with chronic heart failure..
27:65-75.
2006
-
Imaging approach to the assessment of cardiomyopathies using delayed enhancement cardiovascular magnetic resonance..
26:2601-2602.
2005
-
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention..
26:2396-2403.
2005
-
Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes..
26:2106-2113.
2005
-
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry..
26:2114-2119.
2005
-
Moving proximally through the intersection between the process and the content of care in ST-elevation myocardial infarction..
26:1937-1938.
2005
-
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial..
26:1964-1970.
2005
-
A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy..
26:1726-1733.
2005
-
Simplifying risk stratification in non-ST-segment elevation acute coronary syndromes.
26:431-431.
2005
-
Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies..
26:1461-1474.
2005
-
Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial..
26:1506-1512.
2005
-
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry..
26:1063-1069.
2005
-
The effect of intra-aortic balloon counterpulsation on left ventricular functional recovery early after acute myocardial infarction: a randomized experimental magnetic resonance imaging study..
26:1235-1241.
2005
-
Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction..
26:667-674.
2005
-
The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort..
26:421-422.
2005
-
Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality..
26:288-297.
2005
-
Assessing risk in FRISC..
26:103-104.
2005
-
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials..
26:128-136.
2005
-
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry..
25:1911-1919.
2004
-
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..
25:1920-1926.
2004
-
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial..
25:1688-1694.
2004
-
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS..
25:1494-1501.
2004
-
Persistent diastolic dysfunction despite complete systolic functional recovery after reperfused acute myocardial infarction demonstrated by tagged magnetic resonance imaging..
25:1419-1427.
2004
-
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes..
25:313-321.
2004
-
International variation in the use of evidence-based medicines for acute coronary syndromes..
24:2133-2141.
2003
-
Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry..
24:1763-1770.
2003
-
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial..
24:1807-1814.
2003
-
Early hospital discharge after uncomplicated myocardial infarction: are further improvements possible?.
24:1613-1615.
2003
-
International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2..
24:1640-1650.
2003
-
From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE)..
24:1414-1424.
2003
-
ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction..
24:1515-1522.
2003
-
The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2..
24:1024-1034.
2003
-
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study..
24:897-908.
2003
-
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?.
24:522-531.
2003
-
P2275 Plasma homocystein levels independently correlate with angiographic extension of coronary artery disease.
24:436-436.
2003
-
Cardiac markers in acute coronary syndromes-refining our knowledge..
24:136-137.
2003
-
Predictors of 90-day outcome in patients stabilized after acute coronary syndromes..
24:172-181.
2003
-
Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making..
24:182-189.
2003
-
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes..
23:1538-1545.
2002
-
Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion..
23:1449-1455.
2002
-
Determinants of matrix metalloproteinases plasma concentration and activity in premature coronary atherosclerosis.
23:135-135.
2002
-
Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy..
23:1202-1212.
2002
-
Effect of simvastatin on endothelial damage markers and clinical outcomes in acute coronary syndromes.
23:419-419.
2002
-
Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial..
23:1102-1111.
2002
-
Assessment of myocardial viability by cardiovascular magnetic resonance imaging..
23:602-619.
2002
-
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction..
23:550-557.
2002
-
Early invasive strategy for acute coronary syndromes without persistent ST-segment elevation: has the time come for 'drive-through' angiography?.
23:191-194.
2002
-
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker..
23:239-246.
2002
-
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA..
22:2253-2261.
2001
-
ESPRIT in context: pharmacology matters!.
22:1965-1967.
2001
-
Baseline characteristics that identify patients at high risk of death following myocardial infarction. Preliminary findings from the ALIVE trial.
22:700-700.
2001
-
Body mass index remains a significant predictor of outcome after percutaneous coronary interventions in the era of IIbIIIa inhibition.
22:524-524.
2001
-
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study..
22:1601-1612.
2001
-
Eptifibatide (Integrilin (R)) in coronary stent implantation: long-term results of the ESPRIT trial.
22:121-121.
2001
-
Genetic variation in human Stromelysin-1 and Gelatinase B genes and acute coronary syndromes in young males.
22:164-164.
2001
-
Increased rates of stent thrombosis among patients with acute coronary syndromes: insights from two large oral IIb/IIIa antagonist trials.
22:385-385.
2001
-
Low heart rate variability (triangular index method) predicts mortality independent of beta-blocker usage, LVEF, and other factors: ALIVE trial early findings.
22:701-701.
2001
-
Pharmacokinetic and pharmacodynamic responses of the novel factor Xa inhibitor DX-9065a: results from the Xa neutralization for atherosclerotic disease understanding (XaNADU) IB trial.
22:664-+.
2001
-
The ALIVE study: heart rate variability prospectively identifies patients at high risk of death after myocardial infarction.
22:696-+.
2001
-
Peak exercise cardiac power output; a direct indicator of cardiac function strongly predictive of prognosis in chronic heart failure..
22:1496-1503.
2001
-
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial..
21:1967-1978.
2000
-
Lack of progress in cardiogenic shock: lessons from the GUSTO trials..
21:1928-1936.
2000
-
Reperfusion synergism: will it be both sustained and safe?.
21:1913-1916.
2000
-
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators..
21:1750-1758.
2000
-
Inter-regional differences in acute coronary syndrome trials..
21:1397-1399.
2000
-
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction..
21:1502-1513.
2000
-
National and regional registries: what good are they?.
21:1401-1403.
2000
-
Educational level and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial.
21:223-223.
2000
-
Social isolation and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial.
21:213-213.
2000
-
The level of platelet inhibition maintained with a GPIIb/IIIa inhibitor following coronary intervention is strongly associated with the risk of a post-procedural MACE: results of the GOLD study.
21:145-145.
2000
-
Use of a near-patient, whole blood, multi-marker strategy (MMS) for evaluation of patients with chest pain: Results of the CHECKMATE study.
21:19-19.
2000
-
Troponins in pericarditis: implications for diagnosis and management of chest pains patients..
21:798-800.
2000
-
American College of Cardiology/ European Society of Cardiology international study of angiographic data compression phase I. The effects of lossy data compression on recognition of diagnostic features in digital coronary angiography..
21:668-678.
2000
-
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT..
21:371-381.
2000
-
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry..
20:1182-1190.
1999
-
Minimal myocardial damage during coronary intervention is associated with impaired outcome..
20:1112-1119.
1999
-
Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease. FRISC study group. Fragmin during Instability in Coronary Artery Disease..
20:645-652.
1999
-
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III.
20:128-135.
1999
-
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries..
20:128-135.
1999
-
Improved outlook for patients with acute myocardial infarction: an interim progress report..
19:1416-1418.
1998
-
Mechanism of protective effects of ACE inhibition on coronary artery disease..
19 Suppl J:J2-J6.
1998
-
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes..
19 Suppl D:D22-D30.
1998
-
International roundtable on Use of GP IIb/IIIa inhibitors in coronary syndromes: State of the art, Davos, Switzerland, 15-16 February 1997: Foreward.
19.
1998
-
The GUSTO trial and the open artery theory..
18 Suppl F:F2-10.
1997
-
Nebulized prostacyclin for pulmonary hypertension: a step in the right direction..
18:1364-1365.
1997
-
Predictors of outcome of reperfusion therapy..
18:728-735.
1997
-
Pragmatic and mechanistic trials..
18:367-370.
1997
-
Selection of reperfusion therapy for individual patients with evolving myocardial infarction.
18:1371-1381.
1997
-
The rationale for thrombolytic therapy..
17 Suppl E:2-8.
1996
-
Differential expression of angiotensin receptor subtypes in the myocardium: a hypothesis..
17:978-980.
1996
-
Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial..
17:689-698.
1996
-
Serum myoglobin for the early non-invasive detection of coronary reperfusion in patients with acute myocardial infarction..
17:399-406.
1996
-
Erratum: Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial (European Heart Journal (1996) 17 (689-698)).
17:1451.
1996
-
An overview of the results of the EPIC trial..
16 Suppl L:43-49.
1995
-
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor..
16 Suppl L:50-55.
1995
-
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction.
16:1024-1026.
1995
-
Evolution of electrocardiographic and echocardiographic abnormalities during the 4 years following first acute myocardial infarction..
16:1063-1069.
1995
-
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries..
16:1024-1026.
1995
-
Impact of infarct artery patency on the relationship between electrocardiographic and ventriculographic evidence of acute myocardial ischaemia..
15:1356-1361.
1994
-
Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients..
12:1225-1233.
1991
-
Extracellular lipid deposition in atherosclerosis..
11 Suppl E:20-28.
1990
-
Emerging role of the tissue renin-angiotensin systems in congestive heart failure..
11 Suppl B:65-71.
1990
-
In vitro analysis of jets by Doppler colour flow imaging: the importance of time to maximum jet area..
11:361-367.
1990
-
New interventional technology for the management of multivessel coronary artery disease..
10 Suppl H:52-56.
1989
-
Heart rate and metabolic response to competitive squash in veteran players: identification of risk factors for sudden cardiac death..
10:1029-1035.
1989
-
Two-dimensional echocardiography in arrhythmogenic right ventricular dysplasia..
10 Suppl D:22-26.
1989
-
Vascular and renal prostaglandins as counter-regulatory systems in heart failure..
9 Suppl H:15-19.
1988
-
Spontaneously healing infective endocarditis: An unrecognized phenomenon?.
8:327-330.
1987
-
Guidelines for exercise therapy of the elderly after myocardial infarction..
5 Suppl E:121-123.
1984
-
The value of early out-patient cardiac exercise programmes for the elderly in comparison with other selected age groups..
5 Suppl E:113-115.
1984
-
Imaging approach to the assessment of cardiomyopathies using delayed enhancement cardiovascular magnetic resonance: reply.
26:2602-2602.
-
Lessons learned and a look to the future: the Chronic Ischemic Heart Disease (CICD) Pilot Registry.
37:161-163.
-
Association of hepatic steatosis with adverse cardiovascular events: insights from the PROspective Multicenter Imaging Study for Evaluation of chest pain (PROMISE) trial
2018
-
Association of renin-angiotensin system inhibition with clinical outcomes in patients undergoing transcatheter aortic valve replacement: analysis from the STS/ACC TVT Registry
2018
-
Can biomarkers be used to predict cardiopulmonary exercise test performance in patients with chronic heart failure?
2018
-
Cardiac troponin T concentrations are lower in women than men with atrial fibrillation but have similar prognostic value regardless of sex - insights from the ARISTOTLE trial
2018
-
Cluster analysis of cardiovascular risk phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine
2018
-
Elevated biomarkers are associated with increased risk of death and heart failure hospitalization in patients with atrial fibrillation: insights from the ARISTOTLE trial
2018
-
Faster heart rate is associated with significantly higher risk of death and hospitalization due to heart failure in patients with persistent or permanent atrial fibrillation: insights from ARISTOTLE
2018
-
LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS
2018
-
Linear ongoing risk of major cardiovascular events in a global prospective registry of high-risk patients with stable coronary disease: insights from the TIGRIS study
2018
-
Moderate to severe renal insufficiency and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial
2018
-
Normalization of QRS duration to left ventricular dimension improves patient selection for cardiac resynchronization therapy
2018
-
Novel prognostic biomarkers identified by proximity extension assay are associated with major bleeding in patients with atrial fibrillation on oral anticoagulation: insights from the ARISTOTLE trial
2018
-
Predicting recurrent CVD events among adults with stable CVD: a new risk model based on pooled NIH cohorts
2018
-
Use of oral anticoagulation is less among hospitalized patients with paroxysmal compared to persistent or permanent atrial fibrillation
2018
-
A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials
2017
-
Association between the timing of surgery for complicated infective endocarditis and survival
2017
-
Clinical outcomes in patients with atrial fibrillation and echocardiographic risk factors for stroke anticoagulated with apixaban or warfarin
2017
-
Determinants of antithrombotic treatment of patients with AF: baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with AF (IMPACT-AF)
2017
-
Diabetes and cardiovascular risk in patients with symptomatic peripheral artery disease
2017
-
INR prior to bleeding is below 3.0 most of the time in patients with atrial fibrillation using warfarin
2017
-
Low apolipoprotein a1 is significantly associated with decreased risk of cardiovascular events in anticoagulated patients with atrial fibrillation: insights from the ARISTOTLE trial
2017
-
Relationships between cigarette smoking, infarct size, and clinical outcomes in patients undergoing primary PCI For STEMI: a patient-level pooled analysis of 10 randomized trials
2017
-
Serial IL-6 levels and risk of death in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial
2017
-
The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial
2017
-
The occurrence of stroke and TIA in patients with peripheral artery disease and the effect of ticagrelor versus clopidogrel in EUCLID
2017
-
Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial
2017
-
Are clinicians following statin intensity recommendations? Insights in 135 U.S community practices in the PALM registry
2016
-
Comparing novel biomarkers associated with heart failure preserved ejection fraction (HFpEF): A matched case-control analysis
2016
-
Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study
2016
-
Mechanisms and impact on cardiac mortality of right ventricular dysfunction in non-ischaemic cardiomyopathy
2016
-
Multinational ethnic variations in self-reported health status in chronic heart failure patients
2016
-
Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation
2016
-
Patient receptiveness to statin therapy is higher when presented with lifetime risk rather than 10-year risk of cardiovascular disease: insights from the PALM registry
2016
-
Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial
2016
-
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT AF)
2016
-
Pharmacotherapy for atrial fibrillation in patients with chronic kidney disease: insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT AF)
2016
-
Plasma amino acid concentrations are independently associated with adverse outcomes in heart failure and preserved ejection fraction: prognostic utility of amino acid profiles in HFpEF
2016
-
Systemic embolization in patients with atrial fibrillation: results from ROCKET AF
2016
-
The EVEREST II REALISM Continued Access Study-1 year outcomes in patients with functional mitral regurgitation reported by baseline New York Heart Association functional class
2016
-
Biomarker-based risk score for prediction of cardiovascular events in stable coronary heart disease - Experiences from the STABILITY biomarker substudy
2015
-
Characterization of cardiovascular endpoints, impact of event adjudication and effects of darapladib in the STABILITY trial
2015
-
Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without heart failure: insights from the ARISTOTLE trial
2015
-
Effect of ivabradine on heart rate variability in patients with stable coronary artery disease
2015
-
Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation: Insights from the ARISTOTLE trial
2015
-
External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation
2015
-
Hypotension in patients with acute heart failure: Insights from RELAX-AHF
2015
-
Impact of pulmonary hypertension on mortality in patients treated with nitric oxide for failure to wean following cardiothoracic surgery
2015
-
Improved survival after out-of-hospital cardiac arrest most substantial in younger patients - results from a statewide quality improvement initiative in North Carolina during 2010-2013
2015
-
Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study
2015
-
LDL cholesterol remains an important predictor of coronary heart disease events even in the statin era
2015
-
Less non-major bleeding with apixaban versus warfarin among patients with atrial fibrillation: insights from the ARISTOTLE trial
2015
-
Management and clinical consequences of major bleeding in high-risk patients following an acute coronary syndrome. Is aspirin the problem? Insights from the APPRAISE-2 trial
2015
-
Off-hours versus regular hours admission and its relation with long-term mortality of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
2015
-
Outcomes of rivaroxaban versus warfarin in women and men with nonvalvular atrial fibrillation: results from the ROCKET AF trial
2015
-
Rivaroxaban vs. warfarin with concomitant aspirin use in patients with atrial fibrillation: findings from the ROCKET AF trial
2015
-
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for novel oral anticoagulant dose adjustment
2015
-
Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation
2015
-
Survival improved for men but not women, despite increased bystander CPR and first resonder defibrillation for both: results form a statewide quality improvement initiative
2015
-
The EVEREST II REALISM Continued Access study-1 year outcomes in patients with primary mitral regurgitation
2015
-
The evolution of ICD programming practice: What is the relative impact of clinical evidence on clinical practice?
2015
-
Treatment consistency across levels of baseline renal function with rivaroxaban compared with warfarin: insights from ROCKET AF
2015
-
A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score
2014
-
Digoxin use in patients with atrial fibrillation is associated with adverse cardiac outcomes: results from the ROCKET AF trial
2014
-
Future risk of coronary heart disease due to uncontrolled hyperlipidemia in early adulthood
2014
-
Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial
2014
-
Impact of early initiation of intravenous prostanoid therapy in patients with congenital heart disease-related pulmonary arterial hypertension
2014
-
Impact of insurance status on survival in pulmonary hypertension
2014
-
Incidence and impact of patent foramen ovale among patients with pulmonary hypertension
2014
-
Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation
2014
-
Patients with native aortic stenosis represent a high-risk subgroup in nonvalvular atrial fibrillation - Results from ROCKET AF
2014
-
Predictors of and clinical outcomes after internal mammary artery graft failure: insights from the PREVENT-IV trial
2014
-
Relationship between troponin levels and long-term outcomes in medically managed patients with non-ST-segment elevation acute coronary syndromes: insights from the TRILOGY ACS trial
2014
-
The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment
2014
-
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
2014
-
A composite peripheral blood gene expression score has high sensitivity for obstructive coronary artery disease in a non-invasive imaging population and correlates with plaque burden and morphology by
2013
-
A systematic review of outcomes related to hybrid coronary revascularization in patients with multi-vessel coronary artery disease in the drug-eluting stent era
2013
-
ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: an ARISTOTLE substudy
2013
-
Association between type of valve prosthesis and one year mortality in IE: an analysis of 1467 patients from the International collaboration on endocarditis prospective cohort study
2013
-
International variation in management and outcomes in high-risk patients following acute coronary syndromes: results from the APPRAISE-2 trial
2013
-
Mechanical dyssynchrony defined by phase analysis from GSPECT: Does it predict all cause and cardiovascular mortality?
2013
-
Reperfusion arrhythmia bursts predict larger infarct size in STEMI patients undergoing primary percutaneous coronary intervention despite optimal epicardial and microvascular flow
2013
-
Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial
2013
-
Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE
2013
-
Ventricular arrhythmia bursts following primary percutaneous coronary intervention for acute myocardial infarction: correlations with microvascular obstruction and final infarct size using CMR
2013
-
Apixaban after acute coronary syndrome in patients with heart failure: insights from the APPRAISE-2 trial
2012
-
Baseline hemoglobin predicts post-discharge events in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial
2012
-
Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis
2012
-
Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia
2012
-
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial
2012
-
Inadequate anticoagulant therapy during end of study transition to open-label vitamin K antagonist therapy: experience in ROCKET AF
2012
-
Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy
2012
-
Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death
2012
-
NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin
2012
-
New insight into mental stress induced myocardial ischemia: prevalence and demographic/clinical characteristics
2012
-
Racial differences in acute aortic dissection: insights from the International Registry of Acute Aortic Dissection
2012
-
Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial
2012
-
Unmasked pulmonary venous hypertension during vasodilator challenge predicts poor outcomes with medical therapy
2011
-
Acute renal failure after coronary artery bypass surgery: impact of recovery of renal function on long-term mortality
2010
-
No significant increase in the incidence of infective endocarditis following the cessation of antibiotic prophylaxis for dental procedures
2010
-
Prognostic value of Galectin-3 in chronic heart failure: results from the HF-ACTION Study
2010
-
Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the PREVENT-IV trial
2010
-
A practical, validated model for prediction of risk in chronic heart failure
2006
-
Contraindications to cardiac catheterization in non-ST-elevation acute coronary syndromes: Insights from the CRUSADE national quality improvement initiative
2006
-
Fondaparinux results in less bleeding than enoxaparin, irrespective of heparin use, for patients with acute coronary syndromes
2006
-
Low dose enoxaparin in non-ST segment elevation acute coronary syndrome, followed by antiplatelet therapy alone during subsequent percutaneous coronary intervention
2006
-
Patients with acute ST-elevation myocardial infarction and prehospital delay to presentation > 12 hours: high risk of worse outcomes and selective use of reperfusion therapies. The GRACE registry
2006
-
Racial differences in high-risk patients presenting with NSTE ACS: results from the SYNERGY trial
2006
-
Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial
2006
-
Analysis of all recurrent events is superior to the time-to-first event in assessment of drug therapy to prevent ICD therapies
2005
-
Atrial fibrillation carries similar risks in heart failure irrespective of ejection fraction-results from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)
2005
-
Bundle branch block is associated with worse clinical outcomes in heart failure, especially with reduced systolic function: evidence from the CHARM programme
2005
-
Deriving a safety index from the GRACE risk score
2005
-
Determinants of delay in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. The Global Registry of acute coronary events
2005
-
Factors precipitating heart failure hospitalisation: a novel analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
2005
-
Female gender is an independent predictor of better outcome in chronic heart failure: results from the CHARM programme
2005
-
International and time trends in the use and characteristics of patients with acute coronary syndromes treated with clopidogrel: the global registry of acute coronary events experience
2005
-
Intravenous unfractionated heparin, patient profile, and the magnitude of thrombocytopenia are associated with heparin-induced thrombocytopenia (HIT) antibodies: insights from the CATCH registry
2005
-
Predictors of quality of life in symptomatic heart failure patients across the left ventricular ejection fraction spectrum
2005
-
The importance of resting wall motion abnormalities for the diagnostic accuracy of a multicomponent stress CMR test
2005
-
Use of insulin sensitizing agents in outpatients with congestive heart failure appears safe, and may have important clinical benefits when compared with sulfonylureas and insulin
2005
-
Women (especially younger women) with chronic heart failure are less adherent to medication: results from the CHARM program
2005
-
"Leading and lagging" hospitals: can processes of care be used to rank hospitals?
2004
-
Continuous ST-segment recovery analysis is significantly more predictive of mortality than serial static analysis after thrombolytic therapy for acute MI
2004
-
Low haemoglobin is associated with more evidence of congestion but less severe systolic dysfunction in patients with chronic heart failure
2004
-
Substantial reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials
2004
-
2704 Understanding time to treatment in acute myocardial infarction: insights from ASSENT 3 plus
2003
-
755 Relation of myocardial scarring to clinical risk factors for sudden death in hypertrophic cardiomyopathy
2003
-
P1022 A prospective registry of patients hospitalized for worsening heart failure: observations from the IMPACT-HF registry
2003
-
P1102 Mechanism of pexelizumabs mortality benefit in acute myocardial infarction patients treated with primary percutaneous coronary intervention
2003
-
P1627 Does infarct size measured by creatine kinase-MB predict clinical outcomes after fibrinolysis and primary percutaneous coronary intervention?
2003
-
P2848 Enoxaparin versus unfractionated heparin with tenecteplase in the elderly: combined ASSENT-3 and ASSENT-3 PLUS results
2003
-
P2856 Cumulative meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions
2003
-
P2865 Treating patients with acute coronary syndromes with aggressive anti-platelet agents in the grace registry: no observed decrease in in-hospital mortality but increased bleeding complications
2003
-
P2870 Elective percutaneous coronary intervention using anti-platelet therapy alone, without unfractionated heparin or other anti-thrombin therapy
2003
-
Cost-effectiveness of valsartan in patients not receiving angiotensin-converting enzyme inhibitors at baseline
2002
-
Effect of tenecteplase versus alteplase on platelets in patients during the first three hours after acute myocardial infarction
2002
-
How does ST-segment resolution one-hour after fibrinolysis for acute myocardial infarction predict final infarct size? Insights from ASSENT 3
2002
-
Predictors of in-hospital mortality in the global registry of acute coronary events (GRACE)
2002
-
TNK with reduced dose unfractionated heparin associated with similar efficacy and less bleeding: results from ASSENT-2 and ASSENT-3
2002
-
Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure
2001
-
Perspectives gained from large-scale thrombolytic comparative trials.
1996
-
Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers.
1995